MarketLens
Sign Up

Why Did Goldman Sachs Downgrade BioArctic

4 months ago
SHARE THIS ON:

Why Did Goldman Sachs Downgrade BioArctic

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News1 week ago

Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®

Canada's Drug Agency issued a final positive recommendation supporting public reimbursement of Leqembi, BioArctic's Alzheimer's drug partnered with Eisai. The decision could expand market access and s...
Stock News2 weeks ago

Moderna Drops 7% Despite a Fresh Wolfe Research Upgrade, BioNTech Slips

Moderna fell 7%, reversing part of Tuesday's rally, after a Wolfe Research upgrade failed to hold gains. The pullback reopens valuation questions near a $59 billion market cap, with BioNTech also slip...
News1 months ago

Goldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO

Attovia Therapeutics targets a $731.5 million valuation in its upsized US IPO, signaling strong demand for biopharma listings after the Goldman Sachs-backed company expanded its offering.

Breaking News

View All →

Top Headlines

View More →
Stock News1 hour ago

$10,000 in Tesla When It Joined the S&P 500 Would Be About $15,700 Today. An Index Fund Would Have Done Better.

Stock News4 hours ago

J&J Is In Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion

Stock News5 hours ago

Google's Historic 396 MW Clean Energy Deal Just Changed the Game for 1 AI Power Play

Stock News6 hours ago

Better AI Chip Stock: Broadcom vs. Nvidia

Stock News6 hours ago

Dell Technologies Sees AI Boom Building as $95B Server Backlog Signals Demand